SOLENO THERAPEUTICS INC

SOLENO THERAPEUTICS INC is a biopharmaceutical company focused on developing new treatments for rare diseases. The company's primary product candidate, VYKAT TM XR (diazoxide choline) extended-release tablets, previously known as DCCR, received approval from the U.S. Food and Drug Administration (FDA) on March 26, 2025. VYKAT XR is approved for the treatment of hyperphagia in adults and pediatric patients aged four years and older who have Prader-Willi syndrome (PWS). On April 14, 2025, SOLENO THERAPEUTICS INC announced that the first prescriptions of VYKAT XR were delivered to individuals with PWS, and the company began recognizing revenue from VYKAT XR sales during the three months ended June 30, 2025. The company is incorporated in Delaware and has its headquarters in Redwood City, California. VYKAT XR contains diazoxide choline, which is a potent activator of ATP-sensitive potassium (K ATP ) channels. These K ATP channels are crucial in regulating various physiological processes that can be disrupted in several diseases. In PWS, underlying genetic or structural defects can lead to these processes contributing to increased appetite, aggressive food seeking, lack of satiety, excess body fat accumulation, and obesity. VYKAT XR's proposed mechanism of action targets the brain, pancreas, and fat tissue, aiming to broadly impact complex diseases like PWS by reducing appetite, decreasing food seeking, lowering insulin and leptin resistance, and reducing body fat. The company believes it also has the potential to reduce other problematic behaviors associated with PWS. VYKAT XR consists of diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. After solubilization from the formulation, diazoxide choline quickly converts to diazoxide before absorption. It is thought to work by stimulating ion flux through K ATP channels and appears to address PWS signs and symptoms in multiple ways.